83 related articles for article (PubMed ID: 10342381)
1. Anti-HIV-1 activity of combinations and covalent conjugates of negatively charged human serum albumins (NCAs) and AZT.
Kuipers ME; Swart PJ; Witvrouw M; Esté JA; Reymen D; De Clercq E; Meijer DK
J Drug Target; 1999; 6(5):323-35. PubMed ID: 10342381
[TBL] [Abstract][Full Text] [Related]
2. Resistance of the human immunodeficiency virus to the inhibitory action of negatively charged albumins on virus binding to CD4.
Cabrera C; Witvrouw M; Gutiérrez A; Clotet B; Kuipers ME; Swart PJ; Meijer DK; Desmyter J; De Clercq E; Esté JA
AIDS Res Hum Retroviruses; 1999 Nov; 15(17):1535-43. PubMed ID: 10580404
[TBL] [Abstract][Full Text] [Related]
3. Novel, negatively charged, human serum albumins display potent and selective in vitro anti-human immunodeficiency virus type 1 activity.
Jansen RW; Schols D; Pauwels R; De Clercq E; Meijer DK
Mol Pharmacol; 1993 Nov; 44(5):1003-7. PubMed ID: 7902528
[TBL] [Abstract][Full Text] [Related]
4. Comparative pharmacokinetic, immunologic and hematologic studies on the anti-HIV-1/2 compounds aconitylated and succinylated HSA.
Swart PJ; Beljaars E; Smit C; Pasma A; Schuitemaker H; Meijer DK
J Drug Target; 1996; 4(2):109-16. PubMed ID: 8894971
[TBL] [Abstract][Full Text] [Related]
5. Targeting of antiviral drugs to T4-lymphocytes. Anti-HIV activity of neoglycoprotein-AZTMP conjugates in vitro.
Molema G; Jansen RW; Pauwels R; de Clercq E; Meijer DK
Biochem Pharmacol; 1990 Dec; 40(12):2603-10. PubMed ID: 1979734
[TBL] [Abstract][Full Text] [Related]
6. Selective excision of AZTMP by drug-resistant human immunodeficiency virus reverse transcriptase.
Boyer PL; Sarafianos SG; Arnold E; Hughes SH
J Virol; 2001 May; 75(10):4832-42. PubMed ID: 11312355
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and in vitro activity of long-chain 5'-O-[(alkoxycarbonyl)phosphinyl]-3'-azido-3'-deoxythymidines against wild-type and AZT- and foscarnet-resistant strains of HIV-1.
Rosowsky A; Fu H; Pai N; Mellors J; Richman DD; Hostetler KY
J Med Chem; 1997 Aug; 40(16):2482-90. PubMed ID: 9258355
[TBL] [Abstract][Full Text] [Related]
8. Pre-steady-state kinetic characterization of wild type and 3'-azido-3'-deoxythymidine (AZT) resistant human immunodeficiency virus type 1 reverse transcriptase: implication of RNA directed DNA polymerization in the mechanism of AZT resistance.
Kerr SG; Anderson KS
Biochemistry; 1997 Nov; 36(46):14064-70. PubMed ID: 9369478
[TBL] [Abstract][Full Text] [Related]
9. [Adducts of 3'-azido-2,3'-dideoxythymidine 5'-phosphate or 5'-phosphonate as inhibitors of cytopathic effect and transformation of cells under the influence of retroviruses in cell culture].
Fedorov II; Kraevskiĭ AA; Bal'zarinin Zh; De Klerk E
Mol Biol (Mosk); 1992; 26(5):1122-7. PubMed ID: 1470177
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the activation pathway of phosphoramidate triester prodrugs of stavudine and zidovudine.
Saboulard D; Naesens L; Cahard D; Salgado A; Pathirana R; Velazquez S; McGuigan C; De Clercq E; Balzarini J
Mol Pharmacol; 1999 Oct; 56(4):693-704. PubMed ID: 10496951
[TBL] [Abstract][Full Text] [Related]
11. The influence of charge clustering on the anti-HIV-1 activity and in vivo distribution of negatively charged albumins.
Beljaars L; Floris R; Berkhout B; Smit C; Meijer DK; Molema G
Biochem Pharmacol; 2002 May; 63(9):1663-73. PubMed ID: 12007569
[TBL] [Abstract][Full Text] [Related]
12. Cytotoxicity of 3'-azido-3'-deoxythymidine correlates with 3'-azidothymidine-5'-monophosphate (AZTMP) levels, whereas anti-human immunodeficiency virus (HIV) activity correlates with 3'-azidothymidine-5'-triphosphate (AZTTP) levels in cultured CEM T-lymphoblastoid cells.
Törnevik Y; Ullman B; Balzarini J; Wahren B; Eriksson S
Biochem Pharmacol; 1995 Mar; 49(6):829-37. PubMed ID: 7702641
[TBL] [Abstract][Full Text] [Related]
13. Potent in vitro anti-human immunodeficiency virus-1 activity of modified human serum albumins.
Jansen RW; Molema G; Pauwels R; Schols D; De Clercq E; Meijer DK
Mol Pharmacol; 1991 Jun; 39(6):818-23. PubMed ID: 2051994
[TBL] [Abstract][Full Text] [Related]
14. Low-dose, sublingual AZT-monophosphate therapy for HIV+ patients?
Johnson S
Med Hypotheses; 2001 Mar; 56(3):409-10. PubMed ID: 11359372
[TBL] [Abstract][Full Text] [Related]
15. Potent inhibition of replication of primary HIV type 1 isolates in peripheral blood lymphocytes by negatively charged human serum albumins.
Groenink M; Swart PJ; Broersen S; Kuipers M; Meijer DK; Schuitemaker H
AIDS Res Hum Retroviruses; 1997 Jan; 13(2):179-85. PubMed ID: 9007203
[TBL] [Abstract][Full Text] [Related]
16. 3'-Azido-3'-deoxythymidine-(5')-tetraphospho-(5')-adenosine, the product of ATP-mediated excision of chain-terminating AZTMP, is a potent chain-terminating substrate for HIV-1 reverse transcriptase.
Dharmasena S; Pongracz Z; Arnold E; Sarafianos SG; Parniak MA
Biochemistry; 2007 Jan; 46(3):828-36. PubMed ID: 17223704
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and anti-HIV-1 efficacy of negatively charged human serum albumins in mice.
Kuipers ME; Swart PJ; Schutten M; Smit C; Proost JH; Osterhaus AD; Meijer DK
Antiviral Res; 1997 Jan; 33(2):99-108. PubMed ID: 9021051
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of anti-human immunodeficiency virus action of polyoxometalates, a class of broad-spectrum antiviral agents.
Yamamoto N; Schols D; De Clercq E; Debyser Z; Pauwels R; Balzarini J; Nakashima H; Baba M; Hosoya M; Snoeck R
Mol Pharmacol; 1992 Dec; 42(6):1109-17. PubMed ID: 1282664
[TBL] [Abstract][Full Text] [Related]
19. Natural resistance of human immunodeficiency virus type 2 to zidovudine.
Reid P; MacInnes H; Cong ME; Heneine W; García-Lerma JG
Virology; 2005 Jun; 336(2):251-64. PubMed ID: 15892966
[TBL] [Abstract][Full Text] [Related]
20. Suppression of replication of multidrug-resistant HIV type 1 variants by combinations of thymidylate synthase inhibitors with zidovudine or stavudine.
Gao WY; Johns DG; Tanaka M; Mitsuya H
Mol Pharmacol; 1999 Mar; 55(3):535-40. PubMed ID: 10051538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
